Friday June 23, 2017, Leiden (NL)
Safety data are the most common and one of the most important type of data collected in clinical trials. However, in general, the emphasis is on the efficacy data. In this meeting, we will take a look at various aspects of safety data in a clinical trial. Colleagues from industry, academia and regulatory agencies will come together to discuss latest developments for statistical analysis of adverse events, current practices in the conduct of data monitoring committees, and related topics on safety data in clinical trials. We will also hear thoughts on personalized safety analyses.
Confirmed speakers include Maria Costa (GSK), Adam Crisp (GSK), Johannes Hengelbrock (University of Hamburg), Bernd Heinen (JMP), Kit Roes (University of Utrecht), Gerd Rosenkranz (University of Vienna), and Robert Snijder (Astellas).
Astellas Pharma Europe B.V.
For information regarding the scientific content, contact:
Tel: +31 (0)71 545 5968